Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Kura, Kyowa Kirin Start Japan PII Trial of Ziftomenib for AML Filing
Kura Oncology and Kyowa Kirin said on April 24 that the first patient has been dosed in a Japanese PII registrational trial of ziftomenib for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). Under their global collaboration agreement, Kyowa Kirin…
To read the full story
Related Article
- Kura, Kyowa Kirin Land US FDA Approval for AML Med Komzifti
November 17, 2025
- Ziftomenib Given in New AML Cohort in US PI Trial: Kura/Kyowa Kirin
October 3, 2025
- Kura/Kyowa Kirin’s AML Drug Accepted for US FDA Review
June 3, 2025
- Kura/Kyowa Kirin’s AML Drug Inches Closer to FDA Filing on Positive PII Data
February 7, 2025
- Kyowa Kirin, Kura Form Global Collab on Leukemia Drug
November 22, 2024
BUSINESS
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
- AstraZeneca Sees Broad Pipeline, AI Powering 50-Plus Approval Goal
August 5, 2026
- Voyxact PIII Data Confirm Kidney Function Stabilization in IgAN
August 5, 2026
- Perioperative Imfinzi Seen Advancing Gastric Cancer Care: Oncologist
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…